Guidelines for the diagnosis and treatment of alcoholic liver disease
-
-
[1]Lok AS, McMahon BJ.Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) .Chronic hep-atitis B:update of recommendations[J].Hepatology, 2004, 39 (3) ∶857-861. [2]酒依赖与肝病问题调查协作组.中国9个城市4种职业人群酒依赖协作研究 (一) (二) [J].中国心理卫生杂志, 1992, 6 (3) ∶112. [3]厉有名, 陈卫星, 虞朝辉, 等.浙江省酒精性肝病流行病学调查概况[J].中华肝脏病杂志, 2003, 11 (11) ∶647-649. [4]鲁晓岚, 陶明, 罗金燕, 等.饮酒与肝病流行病学调查[J].中华肝脏病杂志, 2002, 10 (6) ∶467-468. [5]黄顺玲, 戴水奇, 张雪红, 等.湖南省酒精性肝病流行病学调查概况[J].中国医师杂志, 2005, 7 (3) ∶426-427. [6]王辉, 王江滨.肝炎病毒感染与酒精性肝硬化关系的研究 (附182例酒精性肝病临床病例报告) [J].白求恩医科大学学报, 1998, 24∶652-653. [7]刘阳, 迟宝荣.酒精性肝硬化237例临床分析[J].吉林医学, 2004, 25 (2) ∶40-42. [8]Shen Z, Li YM, Yu CH, et al.Risk factors for alcohol-related liver injury in the island population of China:a population-based case-control study[J].World J Gastroenterol, 2008, 14 (14) ∶2255-2261. [9]Becker U, Deis A, SΦrensen TI, et al.Prediction of risk of liver disease by alcohol intake, sex, and age:a prospective population study[J].Hepatology, 1996, 23 (5) ∶1025-1029. [10]Kamper-JΦrgensen M, GrΦnbaek M, Tolstrup J, et al.Alcohol and cirrhosis:dose-response or threshold effect-[J].J Hepa-tol, 2004, 41 (1) ∶25-30. [11]Becker U, GrΦnbaek M, Johansen D, et al.Lower risk for alcohol-induced cirrhosis in wine drinkers[J].Hepatology, 2002, 35 (4) ∶868-875. [12]Lu XL, Luo JY, Tao M, et al.Risk factors for alcoholic liver dis-ease in China[J].World J Gastroenterol, 2004, 10 (16) ∶2423-2426. [13]Sato N, Lindros KO, Baraona E, et al.Sex difference in alcohol-related organ injury[J].Alcohol Clin Exp Res, 2001, 25 (5suppl ISBRA) ∶40S-45S. [14]Baraona E, Abittan CS, Dohmen K, et al.Gender differences in pharmacokinetics of alcohol[J].Alcohol Clin Exp Res, 2001, 25 (4) ∶502-507. [15]Wickramasinghe SN, Corridan B, Izaguirre J, et al.Ethnic differ-ences in the biological consequences of alcohol abuse:a comparison between south Asian and European males[J].Alcohol Alcohol, 1995, 30 (5) ∶675-680. [16]Yu C, Li Y, Chen W, et al.Genotype of ethanol metabolizing en-zyme genes by oligonucleotide microarray in alcoholic liver disease in Chinese people[J].Chin Med J (Engl) , 2002, 115 (7) ∶1085-1087. [17]Borrs E, Coutelle C, Rosell A, et al.Genetic polymorphism of al-cohol dehydrogenase in europeans:The ADH2*2allele decreases the risk for alcoholism and is associated with ADH3*1[J].Hep-atology, 2000, 31 (4) ∶984-989. [18]Mendenhall C, Roselle GA, Gartside P, et al.Relationship of pro-tein calorie malnutrition to alcoholic liver disease:a reexamination of data from two Veterans Administration Cooperative Studies[J].Alcohol Clin Exp Res, 1995, 19 (3) ∶635-641. [19]Leevy CM, Moroianu SA.Nutritional aspects of alcoholic liver dis-ease[J].Clin Liver Dis, 2005, 9 (1) ∶67-81. [20]Mezey E.Dietary fat and alcoholic liver disease[J].Hepatology, 1998, 28 (4) ∶901-905. [21]Williams R.Global challenges in liver disease[J].Hepatology, 2006, 44 (3) ∶521-526. [22]中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南[J].中华肝脏病杂志, 2006, 14 (3) ∶164-166. [23]Yersin B, Nicolet JF, Dercrey H, et al.Screening for excessive al-cohol drinking.Comparative value of carbohydrate-deficient trans-ferrin, gamma-glutamyltransferase, and mean corpuscular volume[J].Arch Intern Med, 1995, 155 (17) ∶1907-1911. [24]Conigrave KM, Degenhardt LJ, Whitfield JB, et al.CDT, GGT, and ASTas markers of alcohol use:the WHO/ISBRA collaborative project[J].Alcohol Clin Exp Res, 2002, 26 (3) ∶332-339. [25]Chen CH, Huang MH, Yang JC, et al.Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan[J].J Gastroenterol Hepatol, 2007, 22 (9) ∶1482-1489. [26]Majhi S, Baral N, Lamsal M, et al.De Ritis ratio as diagnostic marker of alcoholic liver disease[J].Nepal Med Coll J, 2006, 8 (1) ∶40-42. [27]Nyblom H, Berggren U, Balldin J, et al.High AST/ALTratio may indicate advanced alcoholic liver disease rather than heavy drinking[J].Alcohol Alcohol, 2004, 39 (4) ∶336-339. [28]Sanyal AJ.American Gastroenterological Association.AGA techni-cal review on nonalcoholic fatty liver disease[J].Gastroenterology, 2002, 123 (5) ∶1705-1725. [29]Graif M, Yanuka M, Baraz M, et al.Quantitative estimation of at-tenuation in ultrasound video images:correlation with histology in diffuse liver disease[J].Invest Radiol, 2000, 35 (5) ∶319-324. [30]Ataseven H, Yildrim MH, Yalniz M, et al.Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis[J].J Hepatol, 2003, 38 (Suppl2) ∶A4177. [31]Farrell GC, George J, Pauline de la MHall, et al.Fatty liver dis-ease:NASHand related disorders[M].Oxford:Blackwell Publish-ing, 2005∶159-207. [32]Srikureja W, Kyulo NL, Runyon BA, et al.MELD score is a betterprognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis[J].J Hepatol, 2005, 42 (5) ∶700-706. [33]Said A, Williams J, Holden J, et al.Model for end stage liver dis-ease score predicts mortality across a broad spectrum of liver disease[J].J Hepatol, 2004, 40 (6) ∶897-903. [34]Carithers RLJr, Herlong HF, Diehl AM, et al.Methylprednisolone therapy in patients with severe alcoholic hepatitis.A randomized multicenter trial[J].Ann Intern Med, 1989, 110 (9) ∶685-690. [35]Tilg H, Day CP.Management strategies in alcoholic liver disease[J].Nat Clin Pract Gastroenterol Hepatol, 2007, 4 (1) ∶24-34. [36]Barve A, Khan R, Marsano L, et al.Treatment of alcoholic liver disease[J].Ann Hepatol, 2008, 7 (1) ∶5-15. [37]O'Shea RS, Dasarathy S, McCullough AJ, et al.Alcoholic liver disease[J].Hepatology, 2010, 51 (1) ∶307-328. [38]Stickel F, Hoehn B, Schuppan D, et al.Reviewarticle:Nutrition-al therapy in alcoholic liver disease[J].Aliment Pharmacol Ther, 2003, 18 (4) ∶357-373. [39]Mathurin P, Mendenhall CL, Carithers RLJr, et al.Corticosteroids improve short-term survival in patients with severe alcoholic hepa-titis (AH) :individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH[J].J Hepatol, 2002, 36 (4) ∶480-487. [40]Imperiale TF, O'Connor JB, McCullough AJ.Corticosteroids are ef-fective in patients with severe alcoholic hepatitis[J].Am J Gastro-enterol, 1999, 94 (10) ∶3066-3068. [41]Shpilenya LS, Muzychenko AP, Gasbarrini G, et al.Metadoxine in acute alcohol intoxication:a double-blind, randomized, placebo-controlled study[J].Alcohol Clin Exp Res, 2002, 26 (3) ∶340-346. [42]Mato JM, Cmara J, Fernndez de Paz J, et al.S-adenosylmethi-onine in alcoholic liver cirrhosis:a randomized, placebo-con-trolled, double-blind, multicenter clinical trial[J].J Hepatol, 1999, 30 (6) ∶1081-1089. [43]邢全台, 袁孟彪, 高新民.思美泰治疗酒精性肝病疗效观察[J].胃肠病学和肝病学杂志, 2002, 11 (3) ∶239-240, 242. [44]Medina J, Moreno-Otero R.Pathophysiological basis for antioxi-dant therapy in chronic liver disease[J].Drugs, 2005, 65 (17) ∶2445-2461. [45]胡国平, 刘凯, 赵连三.多烯磷脂酰胆碱 (易善复) 治疗酒精性肝病和脂肪肝的系统评价[J].肝脏, 2005, 10 (1) ∶5-7. [46]方丽华, 张虹.还原型谷胱甘肽联合利加隆治疗酒精性肝炎疗效观察[J].肝脏, 2004, 9 (3) ∶181-182. [47]张全海, 郭树华, 胡大荣, 等.国产还原型谷胱甘肽治疗酒精性肝病疗效观察[J].中华肝脏病杂志, 2000, 8 (4) ∶239-240. [48]马安林, 刘淑娥, 刘霞, 等.双环醇与多烯磷脂酰胆碱治疗酒精性脂肪肝的临床病理比较[J].临床肝胆病杂志, 2006, 22 (4) ∶272-275. [49]Murray KF, Carithers RLJr, AASLD.AASLD practice guidelines:Evaluation of the patient for liver transplantation[J].Hepatology, 2005, 41 (6) ∶1407-1432.
计量
- 文章访问数: 171
- HTML全文浏览量: 11
- PDF下载量: 1670
- 被引次数: 0